- Company
- Daewoong Nabota is expected to take a global leap
- by Nho, Byung Chul Sep 27, 2022 05:51am
- As Daewoong Pharmaceutical's botulinum toxin product Nabota (Jubo·Jeubeau) is likely to surpass 100 billion won in sales this year, it is drawing attention as it is expanding its global scope as a representative K-toxin product. Nabota, which was launched in Korea in 2014, recorded 15.1 billion won in 2019 It achieved sales of 79.6 billio
- Company
- 4 pharmaceutical companies challenge to add Vemlidy patents
- by Kim, Jin-Gu Sep 27, 2022 05:51am
- Gilead Sciences' patent for hepatitis B treatment Vemlidy (Tenofovir) is increasing. While Dong-A ST, Daewoong Pharmaceutical, Chong Kun Dang, and Jeil succeeded in avoiding patents for the first time in March this year, Samjin, Hutechs, DongKook, and Samil have challenged the same patent for the past two months in a row. According to the pha
- Policy
- MFDS in discord regarding promotion of oral COVID-19 Txs
- by Sep 26, 2022 06:08am
- The government is encouraging the use of oral COVID-19 treatments in high-risk groups, however, accessibility to such has been limited for healthcare professionals due to limitations in emergency use approvals. The Ministry of Food and Drug Safety is being criticized for being passive in making legal interpretations for emergency use autho
- Company
- Praluent can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 26, 2022 06:08am
- PCSK9 inhibitor Praluent has settled on general hospitals. After registering insurance benefits in June 2021, the landing process is steadily underway. According to related industries, Sanofi-Aventis Korea's Praluent passed the Pharmaceutical Affairs Committee (DC), including Samsung Medical Center, Asan Medical Center, Sinchon Severance Hosp
- Company
- The anesthetic drug Byfavo is available in general hospitals
- by Eo, Yun-Ho Sep 26, 2022 06:08am
- Byfavo, the first anesthetic drug in 30 years, has settled on a general hospital prescription. According to related industries, Hana Pharmaceutical's Byfavo passed the Drug Commission (DC) of Big 5 General Hospitals, including Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital. Byfavo is a new anestheti
- Policy
- Lipiodol’s price reduced from 25th... 2-year suit dismissed
- by Kim, Jung-Ju Sep 26, 2022 06:07am
- The price of Guerbet Korea’s liver cancer contrast medium, Lipiodol Ultra-Fluid (iodized oil, 12.8g/10mL), which had been under legal dispute for the past 2 years after the government decided to remove the drug from the reimbursement list, will be reduced from the 25th this month. This is because the pricing discount that had been ori
- Company
- Half of pts with macular degeneration have ↓ effect
- by Sep 26, 2022 06:07am
- Researchers expect the new VEGF inhibitor Beovu to address unmet demand. Patients with neovascular age-related macular degeneration in Korea had more than half of retinal exudates at the time of one year of treatment, indicating that the vision improvement effect was not significant. It was found in PROOF, which evaluated the retinal exudate
- Policy
- HCV treatment Epclusa·Vosevi start pricing negotiations
- by Lee, Tak-Sun Sep 23, 2022 05:52am
- The National Health Insurance Service is known to be conducting pricing negotiations with Gilead Science Korea for the company’s new Hepatitis C treatments, ‘Vosevi (sofosbuvir/velpatasvir/voxilaprevir)’ and ‘Epclusa (sofosbuvir/velpatasvir).’ The two drugs received conditional approval from the Drug Reimbursement Evaluation Committee
- Company
- Nubeqa can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 23, 2022 05:52am
- Nubeqa, a prostate cancer treatment, can be prescribed at general hospitals. According to related industries, Bayer Korea's oral androgen receptor inhibitor (ARi) Nubeqa for nmCRPC treatment passed the DC of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul Asan Hospital, and Sinchon Severance Hosp
- Policy
- On-site inspections of overseas plants will resume next year
- by Lee, Hye-Kyung Sep 23, 2022 05:52am
- On-site inspections of overseas biopharmaceutical manufacturing plants, which have been suspended due to COVID-19, will resume. The Ministry of Food and Drug Safety's Biopharmaceutical Quality Management Division recently sent an official letter to representatives of biopharmaceutical importers, the KOBIA, the KPBMA, Korea Pharmaceutical Trad
